Skip to main content

Table 1 Summary of the pooled efficacy outcome

From: Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials

Outcome or subgroup Studies Cases No. with event/total no. of patients
INIs and EFV
Effect estimate (RR and 95% CI)
Virologic suppression 3 672 231/350 and 223/322 0.94 (0.85,1.05)
 DTG vs. EFV 1 113 52/69 and 36/44 0.92 (0.76,1.12)
 RAL vs. EFV 2 559 179/281 and 187/278 0.95 (0.84,1.07)
Bacteriology suppression 3 672 313/350 and 288/322 1.00 (0.95,1.05)
 DTG vs. EFV 1 113 61/69 and 40/44 0.97 (0.86,1.10)
 RAL vs. EFV 2 559 252/281 and 248/278 1.01 (0.95,1.06)
Adherence 3 617 309/321 and 291/296 0.98 (0.95,1.01)
 DTG vs. EFV 1 99 56/58 and 38/41 1.04 (0.94,1.15)
 RAL vs. EFV 2 518 253/263 and 253/255 0.97 (0.94,1.00)